<![CDATA[FDA Grants Priority Review to Enhertu as Treatment for Patients with HER2-positive Early Breast Cancer ]]>
FDA granted Priority Review to AstraZeneca’s supplemental application for Enhertu in early-stage HER2-positive breast cancer, moving the drug closer to a potential new indication for patients at high risk of recurrence following initial treatment. The …